Investor Relations

Investor Relations

Invest in Quadrant Biosciences

Invest in Quadrant Biosciences

We just launched the world’s first epigenetic saliva test for autism

Investment opportunity available now.

We just launched the world’s first epigenetic saliva test for autism

Investment opportunity coming soon. Be first in line.

rich uhlig founder-4
Developed in medical research labs at SUNY Upstate Medical University and Penn State College of Medicine, the Clarifi™ diagnostic platform leverages new discoveries in epigenetics and the microbiome to provide first of its kind diagnostic solutions to many of today’s critical health care challenges. Clarifi™ ASD, the first ever biological diagnostic aid for autism spectrum disorder, has just launched commercially in the U.S.

Developed in medical research labs at SUNY Upstate Medical University and Penn State College of Medicine, the Clarifi™ diagnostic platform leverages new discoveries in epigenetics and the microbiome to provide first of its kind diagnostic solutions to many of today’s critical health care challenges. Clarifi™ ASD, the first ever biological diagnostic aid for autism spectrum disorder, has just launched commercially in the U.S.

As seen on

News room

Groundbreaking autism test developed in CNY would diagnose children through saliva
CNY Central | December 2019

Traditionally, children who are thought to have autism are put through a series of practical tests. About one in 59 children are diagnosed with Autism Spectrum Disorder in the United States, according to the CDC.

Saliva test for autism hits market; Syracuse research could lead to faster help for kids
Syracuse | December 2019

A saliva test designed to quickly diagnose autism in toddlers has hit the market after seven years of research at SUNY Upstate Medical University and Penn State.

Microbes in Saliva May Offer Way of Detecting and Understanding Early Stages of Parkinson’s, Study Says
Parkinsons News Today | July 2019

A saliva test to detect oral microbes may offer an accurate way of detecting Parkinson’s in its early stages and further understanding of the disease, a study reports.

Quadrant Biosciences Recognized as New York Technology Business of the Year
Market Watch | May 2019

Quadrant Biosciences Inc. has been awarded the Technology Business of the Year by the New York State Small Business Development Center (SBDC).

Study finds correlation between specific epigenetic molecules and autism traits
BioSpace | April 2019

Scientists have discovered certain molecules in the saliva that not only differentiate children with autism spectrum disorder (ASD), but appear to correlate with specific autism traits.

Press releases

Quadrant Biosciences Launches First Ever Epigenetic Saliva Test for Autism - December 4, 2019
New Research shows link between Parkinson's disease and the microbiome - July 01, 2019
The oral microbiome may yield early biomarker for the disease.

A simple saliva swab may provide an accurate way of detecting Parkinson’s disease in its earliest stages, according to a study just published in the journal Plos One.

Quadrant Biosciences Recognized as New York Technology Business of the Year - May 7, 2019
Company’s Innovative Technology Recognized for its Social and Economic Impact

Quadrant Biosciences Inc. has been awarded the Technology Business of the Year by the New York State Small Business Development Center (SBDC).

Quadrant Biosciences Partners with Leading Edge Genomic Testing Company Admera Health - August 08, 2018
Rising companies in diagnostic space form strategic partnership.

Quadrant Biosciences Inc., an emerging life science company based in Syracuse, New York, is pleased to announce its strategic partnership with Admera Health, an advanced molecular diagnostics company headquartered in South Plainfield, NJ.

Wall Street Veteran Peter Cohen joins Quadrant Biosciences Board of Directors - April 24, 2018
Quadrant Biosciences Inc., a Syracuse, New York-based Life Science company, announced today that Wall Street veteran Peter Cohen will be joining its Board of Directors.

Mr. Cohen is currently Chairman of the Board of Cowen Inc., a well-known diversified financial services firm. Quadrant Bioscience, which focuses on the development of functional assessment and epigenetic biomarkers for various neurological conditions…

Published research

The oral microbiome of early stage Parkinson’s disease and its relationship with functional measures of motor and non-motor function
Parent Perspectives Towards Genetic and Epigenetic Testing for Autism Spectrum Disorder
Saliva MicroRNA Differentiates Children With Autism From Peers With Typical and Atypical Development
A Review of MicroRNA Biomarkers in Traumatic Brain Injury
Comparison of serum and saliva miRNAs for identification and characterization of mTBI in adult mixed martial arts fighters
Validation of a Salivary RNA Test for Childhood Autism Spectrum Disorder

Why invest in
Quadrant Biosciences?

Interested in learning more about investing?

World’s first epigenetic diagnostic aid for autism

We have just commercially launched the world’s first epigenetic diagnostic aid for autism.

Successfully raised over $30 million

We have successfully raised over $30 million from private investors who believe in what we are doing; and we have received nearly $3 million in funding awards from the NIH* and others.

Global leaders in the development of epigenetic diagnostics

We are among the global leaders in the development of epigenetic diagnostic tools for neurological conditions and have a diverse pipeline of products. Clarifi ASD is just the beginning. Several other products based on our epigenetic diagnostic science are currently under development including saliva tests for concussion and Parkinson’s disease.

Experienced management team

We have assembled a seasoned management team, as well as a experienced medical advisory board comprised of recognized leaders in the areas of autism and epigenetic research to confidently guide us into the future.

What is a Regulation A offering?

Regulation A is an exemption from SEC registration that allows early stage companies to raise funds for all types of investors, including “non-accredited” investors.

How & where do we purchase the shares?

The offering is now available. We are working with a company called Wefunder which provides a platform for you to learn about our company and the investment opportunity and, if interested, safely, simply, and securely make an investment. Visit our Wefunder page for more details.

What is the minimum investment?

We expect that the minimum investment will be $300, which is
100 shares at the $3.00/share price. 

Learn more about
Clarifi ASD

Investment opportunity

The science behind Clarifi

Early diagnosis: parent perspective

Who we are

Meet the team

We have assembled a seasoned management team, as well as an experienced medical advisory board comprising recognized leaders in the areas of autism and epigenetic research to confidently guide us into the future.

Our Board of Directors is composed of individuals with substantial knowledge and experience in the areas of finance, law, medicine, operations, intellectual property, and sales.

Our research partners

We are privileged to have partnered with a number of outstanding research universities and organizations to help further our epigenetic research.

International

We have entered into a research partnership with EU Aims – a Europe-wide collaboration between organizations representing autistic people and their families, academia and industry.

The science behind the
Clarifi diagnostic platform

Innovative technology

Clarifi represents a new approach to autism diagnosis. It is based on RNA rather than DNA. Epigenetics rather than genetics.

Every gene that encodes a protein comes under the influence of non-coding RNAs, such as miRNA’s, in terms of whether it makes that protein and how much of that protein is made. These RNAs are involved in a wide range of biological processes in the body, making them a robust source of biomarkers for autism.

Using state of the art next-generation sequencing, researchers at SUNY Upstate Medical University, Penn State College of Medicine, and Quadrant Biosciences identified a broad panel of RNA features useful in diagnosing autism. These include both non-coding human RNAs such as miRNA and piRNA, as well as microbial RNAs associated with specific bacteria in the microbiome.

Product pipeline

Clarifi ASD is just the beginning. Several other products based on the Clarifi Epigenetic Diagnostic Platform are currently under development including saliva tests for concussions and Parkinson’s disease.

Quadrant Biosciences accomplishments

Key autism statistics

Trending on social media

2020 Conference Schedule

  • MAPS Spring 2020, Functional & Translational Medicine Conference – March 19th – 21st | Orlando, FL
  • Nurse Practitioner Conference – March 25th – 28th | Long Beach, CA
  • Any Baby Can – April 18th | Texas
  • Society of Pediatric Nurses – April 22nd – 25th | Anaheim, CA
  • Pediatric Academic Societies Meeting – April 29th – May 6th | Philadelphia, PA
  • American College of Osteopathic Pediatricians – April 30th – May 3rd | Colorado Springs, CO
  • Pri-Med West – May 6th – 9th | Anaheim, CA
  • 2020 AANP  – June 23rd – 28th | New Orleans, LA
  • Integrative Medicine for Mental Health Conference  – August 20th – 23rd | Chicago, IL
  • FCAAP Future of Pediatrics  – September 4th – 6th | Orlando, FL
  • AAP 2020  – October 3rd – 6th | San Diego, CA
  • Society of Developmental & Behavioral Pediatrics  – October 9th – 12th | Austin, TX
  • Texas Pediatric Society  – October 15th – 18th | Galveston, TX
  • Family Medicine Experience AAFP  – October 13th – 17th | Chicago, IL
  • OMED Annual Meeting  – October 16th – 20th | Austin, TX
  • Child Neurology Society Meeting – October 19th – 23rd | San Diego, CA
  • American Academy of Child & Adolescent Psychiatry  – October 19th – 24th | San Francisco, CA

What are people saying

Charitable involvement

Giving back

We support a number of organizations including Autism Nature Trail, PKAN research, Autism Speaks, Echo Autism, Autism Treatment Center, & Any Baby Can.

Learn more about investing with us

Investments in Quadrant Biosciences are speculative and involve risks. Risks include but are not limited to, illiquidity, complete loss of capital, regulatory risks, and valuation risks. See the offering circular for a complete discussion of risks.

*This research is supported by the National Institutes of Health under Applications Number R42 MH111347-02A1; 5R42MH111347-03; and 3R42MH111347-02A1S1. This content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT. YOU MAY OBTAIN A COPY OF THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT FROM HERE.
YOU SHOULD READ THE OFFERING CIRCULAR BEFORE MAKING ANY INVESTMENT.
See the NCPS Offerings Disclosure here.
Securities offered through North Capital Private Securities, member FINRA/SIPC.

THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.